11health Raises £1.25 Million from Leading City Figures

11health, a British medical technology business, has completed a new round of funding, raising a total of £775,000 from six angel investors, on top of the initial funding round of £500,000. This brings the total funding to over £1.25 million. This round of funding enables the business to extend the management team and more effectively pursue an aggressive sales and marketing strategy in the UK and the US. It will also further establish the award-winning Ostom-i Alert as the leading medical device for bowel disease patients and develop other connected device products across the healthcare marketplace.

To support the growth strategy, 11health has appointed James Barbour-Smith as Executive Chairman. He will be responsible for the continued financial growth and strategic direction of the firm. James brings to the role over 20 years of global experience in developing and building businesses through his role as Head of Portfolio at Gresham Private Equity.

As part of its US growth strategy, 11health has hired Matthew Wilder, who joins the US team as Vice President of Sales. Matthew will be responsible for implementing sales and driving growth across America. Matthew has extensive experience in medical sales and played for the American Football Team, The Miami Dolphins. The firm is in advanced discussions and trials with a number of well-respected hospitals in the U.S. including: Stanford University, Massachusetts General and Cedars Sinai (LA).

Michael Seres, Founder, 11health said: "We are pleased to welcome James and Matthew to 11health and look forward to the unique contribution that they will bring to the business. As a connected device company, focused initially on stoma care, our ambition is to become the leading connected device across all medical bags and pouches. These important new appointments, along with this funding will reinforce our growing presence in the U.S. and British markets, and help bring our global vision to reality."

He continued: "We are moving forward at a tremendous pace, and this additional funding will really help us accelerate our product development especially into new markets and build out our sales teams in the UK and in the U.S."

Michael Seres, a long-term patient turned innovator, founded 11health in 2013 with Adam Bloom when he created the Ostom-i Alert device from his hospital bed, after being the 11th person in the UK to undergo a small bowel transplant in 2011.

About 11health
11health is a fast-growing British medical technology business, co-founded in 2013 by Michael Seres and Adam Bloom. Michael was diagnosed with the incurable bowel condition Crohn’s Disease aged 12. After over 20 operations and intestinal failure he became the 11th person to undergo a small bowel transplant in the UK at The Churchill Hospital, Oxford, England. His own experience as an ostomy patient led him to designing the initial Ostom-i prototype whilst recovering from transplant.

A published author and professional speaker Michael was a Stanford Medicine X e-patient scholar (2011) and develops patient engagement strategies for hospitals, primary care trusts and patient groups. He has a background in consumer product licensing and merchandising having worked with major brands such as FIFA, UEFA, The X Factor and The Apprentice. He is the patient lead for the main UK health twitterchat #NHSSM & digital strategy advisor to The Oxford Transplant Foundation where he helped implement the first skype clinics.

Most Popular Now

Philips Foundation 2024 Annual Report: E…

Marking its tenth anniversary, Philips Foundation released its 2024 Annual Report, highlighting a year in which the Philips Foundation helped provide access to quality healthcare for 46.5 million people around...

New AI Transforms Radiology with Speed, …

A first-of-its-kind generative AI system, developed in-house at Northwestern Medicine, is revolutionizing radiology - boosting productivity, identifying life-threatening conditions in milliseconds and offering a breakthrough solution to the global radiologist...

Scientists Argue for More FDA Oversight …

An agile, transparent, and ethics-driven oversight system is needed for the U.S. Food and Drug Administration (FDA) to balance innovation with patient safety when it comes to artificial intelligence-driven medical...

New Research Finds Specific Learning Str…

If data used to train artificial intelligence models for medical applications, such as hospitals across the Greater Toronto Area, differs from the real-world data, it could lead to patient harm...

Giving Doctors an AI-Powered Head Start …

Detection of melanoma and a range of other skin diseases will be faster and more accurate with a new artificial intelligence (AI) powered tool that analyses multiple imaging types simultaneously...

AI Agents for Oncology

Clinical decision-making in oncology is challenging and requires the analysis of various data types - from medical imaging and genetic information to patient records and treatment guidelines. To effectively support...

Patients say "Yes..ish" to the…

As artificial intelligence (AI) continues to be integrated in healthcare, a new multinational study involving Aarhus University sheds light on how dental patients really feel about its growing role in...

'AI Scientist' Suggests Combin…

An 'AI scientist', working in collaboration with human scientists, has found that combinations of cheap and safe drugs - used to treat conditions such as high cholesterol and alcohol dependence...

Brains vs. Bytes: Study Compares Diagnos…

A University of Maine study compared how well artificial intelligence (AI) models and human clinicians handled complex or sensitive medical cases. The study published in the Journal of Health Organization...

Start-ups in the Spotlight at MEDICA 202…

17 - 20 November 2025, Düsseldorf, Germany. MEDICA, the leading international trade fair and platform for healthcare innovations, will once again confirm its position as the world's number one hotspot for...